Hypofractionated Radiation Therapy for Merkel Cell Carcinoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT05100095
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Merkel Cell Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Radiation therapy — DRUG
    Hypofractionated radiation therapy to the primary tumor and/or lymph nodes

Study Details

This phase II trial tests whether hypofractionated radiation works to treat patients with Merkel cell carcinoma. Radiation therapy uses high energy radio waves to kill cancer cells and shrink tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may be more convenient for patients and less immunosuppressive.

Key Dates

Start date
Dec 14, 2021
Status verified
Jan 2026
Primary completion
Sep 1, 2028
Completion
Sep 1, 2028

Study Design

Enrollment
52 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Radiation therapy
    Patients receive radiation therapy in 10 daily fractions (M-F) over 2 weeks.

Primary Outcome Measure

To establish the 2-year local control rate for adjuvant hypofractionated RT to the primary tumor bed. And to establish the 2-year nodal control rate for adjuvant hypofractionated RT to the primary draining nodal bed. [ Time Frame: through study completion, an average of 2 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
M D Anderson Cancer CenterHoustonTexas77030
Devarati Mitra
[email protected]
713-563-1339

Find similar trials in Houston, TX

By research site
M D Anderson Cancer Center· Houston, TX

Related Studies